NORTH CHICAGO (dpa-AFX) - Abbott Laboratories (ABT) Tuesday announced CE Mark in Europe for the Xience Xpedition 48 Everolimus Eluting Coronary Stent System, the first-of-its-kind treatment for very long blockages in the vessels that supply blood to the heart due to coronary artery disease or CAD.
According to the company, Xience Xpedition 48 leverages the proven design and clinical outcomes of the Xience family of drug eluting stents in a unique 48 mm length.
Xience Xpedition 48 is supported by strong clinical evidence from the Xience family of drug eluting stents, including data from over 53,000 patients across more than 100 studies with long-term outcomes out to five years.
The safety of the Xience family of drug eluting stents has been consistently demonstrated in several clinical trials representative of routine clinical practice, Abbott said.
The company added that Xience family has one of the broadest ranges of CE Mark indications for drug eluting stents on the market in Europe, including indications to treat patients with complex disease such as diabetes.
Copyright RTT News/dpa-AFX
© 2013 AFX News
